Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 655.00
Bid: 658.00
Ask: 659.00
Change: -0.50 (-0.08%)
Spread: 1.00 (0.152%)
Open: 643.00
High: 664.00
Low: 643.00
Prev. Close: 655.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 May 2020 07:00

RNS Number : 7367L
Tate & Lyle PLC
04 May 2020
 

4 May 2020 - Tate & Lyle PLC

 

 

TATE & LYLE TRADING UPDATE FOR APRIL IN RELATION TO COVID-19

 

Introduction

Tate & Lyle will issue its results for the year ended 31 March 2020 on 21 May 2020. The Group performed well during the year with each trading division exceeding the prior year's performance. Accordingly, we expect to announce results slightly ahead of our guidance coming into the year.

 

While trading in March showed limited impact from the Covid-19 pandemic, the lockdowns in place in many countries across the world throughout April, most notably in our largest markets of the US and Europe, have led to some significant changes in demand patterns for our products. This statement provides an update on trading in April based on the information currently available and the actions we are taking.

 

Our priorities continue to be the health, safety and wellbeing of our colleagues, their families and the local communities where we operate, and to serve our customers in these difficult times. Strict hygiene and protective measures are in place across our business, we are working closely with our customers to respond quickly to their changing needs and all our manufacturing facilities have remained fully operational during the pandemic.

 

Trading in April 2020

Food & Beverage Solutions and Sucralose continued to perform well with volume for Food & Beverage Solutions in line with the comparative period and Sucralose 18% higher due to phasing of customer orders. Earlier in the month, demand was strong for ingredients used in packaged and shelf-stable foods as consumers in North America and Europe filled their pantries for consumption at home. As the month progressed, this was offset by lower demand for products consumed out-of-home, such as in the food service sector in North America.

 

Primary Products volume was significantly impacted by the first full month of lockdown in the US. Bulk sweetener volume was 26% lower from reduced out-of-home consumption as bars, cinemas, restaurants and sporting events were either shut or cancelled. Industrial starch volume was 9% lower reflecting reduced demand for paper and packaging following the closure of schools, offices and a general decline in economic activity. Commodities were also impacted as ethanol prices decreased sharply.

 

The financial impact of lower demand was partially mitigated by prompt actions taken in March to optimise cash and reduce costs as we saw the pandemic unfolding. These included freezing salary increases and recruitment, stopping non-essential discretionary spend and reprioritising capital commitments.

 

We will provide more information when we announce our full-year results on 21 May 2020 and going forward as necessary.

 

Strong balance sheet

We continue to have a strong financial position and balance sheet. Our leverage is low with net debt / EBITDA of 0.9x at 31 March 2020 (0.6x on a covenant basis) and strong liquidity with access to over US$1 billion through cash on hand and a revolving credit facility. We also have significant covenant headroom on borrowings (covenant: net debt / EBITDA not greater than 3.5x) and no debt maturity until 2023.

 

Nick Hampton, Chief Executive of Tate & Lyle said:

"I am delighted with our performance over the last financial year and the progress we are making executing our strategy and living our purpose.

 

I am also very proud of the way we have responded to the unprecedented challenges of Covid-19. From the outset of the pandemic, our priority has been to look after our employees and local communities, keep our operations running and support our customers. The fact that all our manufacturing facilities have remained fully operational during the pandemic and customer orders have continued to be fulfilled, often at very short notice, is a testament to the commitment and skill of all our employees.

 

Tate & Lyle is a resilient business that meets challenges head-on. I am confident that with the strength of our portfolio, people and operating capabilities we will navigate this period successfully and that our future prospects remain strong."

 

END

 

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Andrew Lorenz, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7775 641 807

 

About Tate & Lyle:

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEAFSDEFFEEFA
Date   Source Headline
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.